目的 探討培坤丸聯(lián)合戊酸雌二醇治療月經(jīng)不調(diào)的臨床療效。方法 選取2021年1月—2022年1月中山市小欖人民醫(yī)院收治的106例月經(jīng)不調(diào)患者,按照隨機(jī)數(shù)字表法分為對(duì)照組和治療組,每組各53例。對(duì)照組于月經(jīng)周期第5天開始口服戊酸雌二醇片,1 mg/次,1次/d,連續(xù)用藥21 d為1個(gè)周期。治療組在對(duì)照組基礎(chǔ)上口服培坤丸,9 g/次,2次/d。兩組療程均為3個(gè)月經(jīng)周期。觀察兩組的臨床療效,比較治療前后兩組月經(jīng)不調(diào)癥狀評(píng)分、月經(jīng)癥狀量表(MDQ)評(píng)分、90項(xiàng)癥狀自評(píng)量表(SCL-90)總分、36項(xiàng)健康調(diào)查簡(jiǎn)表(SF-36)總分及血清性激素[孕酮(P)、雌二醇(E₂)、促卵泡刺激素(FSH)、促黃體生成素(LH)]水平。統(tǒng)計(jì)兩組不良反應(yīng)情況。結(jié)果 治療后,治療組總有效率是96.23%,顯著高于對(duì)照組的84.91%(P<0.05)。治療后,兩組小腹脹痛評(píng)分、腰骶酸痛評(píng)分、精神不振評(píng)分、乳房脹痛評(píng)分、神疲乏力評(píng)分、少氣懶言評(píng)分均顯著降低(P<0.05),且治療后治療組月經(jīng)不調(diào)癥狀評(píng)分低于對(duì)照組(P<0.05)。治療后,兩組MDQ評(píng)分、SCL-90總分均顯著降低,而SF-36總分均顯著增加(P<0.05),均以治療組改善更顯著(P<0.05)。治療后,兩組血清P、E₂水平均顯著上升,而血清FSH、LH水平均顯著下降(P<0.05),治療后,治療組血清性激素水平改善更顯著(P<0.05)。治療后,治療組和對(duì)照組不良反應(yīng)發(fā)生率分別是5.66%、3.77%,差異無(wú)統(tǒng)計(jì)學(xué)意義。結(jié)論 培坤丸聯(lián)合戊酸雌二醇治療月經(jīng)不調(diào)有確切療效,能有效減輕患者月經(jīng)不調(diào)相關(guān)癥狀,改善心理健康狀態(tài)和生活質(zhì)量,調(diào)節(jié)機(jī)體性激素分泌水平,且患者耐受性較好。

Objective To investigate the clinical effect of Peikun Pills combined with estradiol valerate in treatment of menstrual disorder.Methods A total of 106 patients with irregular menstruation admitted to Zhongshan Xiaolan People's Hospital from January 2021 to January 2022 were randomly divided into two groups according to random number table method. Patients in the control group were po administered with Estradiol Valerate Tablets from the 5th day of the menstrual cycle, 1 mg/time, once daily. 21 Days of continuous drug usage was a cycle. Patients in the treatment group were po administered with Peikun Pills on the basis of the control group, 9 g/time, twice daily. The treatment course of both groups was 3 menstrual cycles. After treatment, the clinical efficacy of the two groups was observed. The score of menstrual disorder symptoms, the score of Menstrual Symptom Scale(MDQ), the score of 90-item Symptom Self-Rating Scale(SCL-90), the score of 36-item Health Survey Brief Form(SF-36), and the levels of serum sex hormones [progesterone(P), estradiol(E₂), follicle-stimulating hormone(FSH), luteinizing hormone(LH)] before and after treatment were compared between the two groups. The adverse reactions of the two groups were analyzed.Results After treatment, the total effective rate of the treatment group was 96.23%, significantly higher than that of the control group(84.91%)(P<0.05). After treatment, lower abdominal distension pain score, lumbosacral pain score, lethargy score, breast distension pain score, fatigue score,low qi lazy talk score were significantly decreased in both groups(P<0.05), and after treatment, the score of irregular menstruation symptom in the treatment group was lower than that in the control group(P<0.05). After treatment, MDQ score and SCL-90 score were significantly decreased in both groups, while SF-36 score were significantly increased(P<0.05), and the improvement was more significant in the treatment group(P<0.05). After treatment, serum P and E₂ levels were significantly increased in both groups, while serum FSH and LH levels were significantly decreased(P<0.05). After treatment, serum sex hormone levels in the treatment group were more significantly improved(P<0.05). After treatment, the incidence of adverse reactions in the treatment group and the control group was 5.66% and 3.77%, respectively, with no statistically significant difference.Conclusion Peikun Pills combined with estradiol valerate has definite curative effect in treatment of menstrual disorder, and can effectively reduce the symptoms related to irregular menstruation, improve mental health status and quality of life, which can regulate the body sex hormone secretion level with good tolerance.

R984

中山市醫(yī)學(xué)科研項(xiàng)目(2021J355)